FY2027 Earnings Estimate for COGT Issued By Leerink Partnrs

Cogent Biosciences, Inc. (NASDAQ:COGT) – Leerink Partnrs boosted their FY2027 earnings per share (EPS) estimates for Cogent Biosciences in a report released on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now forecasts that the technology company will earn $0.69 per share for the year, up from their previous forecast of $0.61. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.29) per share.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, November 12th. The technology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). During the same period in the prior year, the firm posted ($0.64) EPS.

A number of other equities research analysts have also weighed in on the company. Citigroup lifted their price objective on Cogent Biosciences from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Robert W. Baird upped their price objective on Cogent Biosciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a report on Thursday, September 5th. Needham & Company LLC cut their price objective on Cogent Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Cogent Biosciences in a research report on Monday, November 4th. Finally, Wedbush reiterated a “neutral” rating and issued a $11.00 price target on shares of Cogent Biosciences in a report on Tuesday. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $14.83.

Cogent Biosciences Stock Down 7.8 %

Shares of Cogent Biosciences stock opened at $8.90 on Friday. The firm has a market cap of $974.11 million, a price-to-earnings ratio of -3.59 and a beta of 1.72. Cogent Biosciences has a 52-week low of $3.67 and a 52-week high of $12.61. The company’s 50-day simple moving average is $10.99 and its 200-day simple moving average is $9.55.

Institutional Trading of Cogent Biosciences

Large investors have recently bought and sold shares of the company. Values First Advisors Inc. acquired a new position in shares of Cogent Biosciences during the 3rd quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. raised its position in Cogent Biosciences by 38.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company’s stock worth $43,000 after acquiring an additional 1,104 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Cogent Biosciences by 234.5% in the first quarter. Russell Investments Group Ltd. now owns 10,014 shares of the technology company’s stock valued at $67,000 after purchasing an additional 7,020 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Cogent Biosciences in the third quarter valued at approximately $76,000. Finally, Quest Partners LLC purchased a new position in shares of Cogent Biosciences during the 2nd quarter worth approximately $89,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.